IL154080A0 - Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases - Google Patents

Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases

Info

Publication number
IL154080A0
IL154080A0 IL15408001A IL15408001A IL154080A0 IL 154080 A0 IL154080 A0 IL 154080A0 IL 15408001 A IL15408001 A IL 15408001A IL 15408001 A IL15408001 A IL 15408001A IL 154080 A0 IL154080 A0 IL 154080A0
Authority
IL
Israel
Prior art keywords
spiroheterocyclic
cysteine proteases
reversible inhibitors
nitriles useful
nitriles
Prior art date
Application number
IL15408001A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of IL154080A0 publication Critical patent/IL154080A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ceramic Engineering (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Structural Engineering (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
IL15408001A 2000-09-08 2001-03-14 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases IL154080A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/655,351 US6420364B1 (en) 1999-09-13 2000-09-08 Compound useful as reversible inhibitors of cysteine proteases
PCT/US2001/008084 WO2002020485A1 (en) 2000-09-08 2001-03-14 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases

Publications (1)

Publication Number Publication Date
IL154080A0 true IL154080A0 (en) 2003-07-31

Family

ID=24628539

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15408001A IL154080A0 (en) 2000-09-08 2001-03-14 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases

Country Status (24)

Country Link
US (10) US6420364B1 (enExample)
EP (1) EP1322613A1 (enExample)
JP (1) JP2004508356A (enExample)
KR (1) KR20030051644A (enExample)
CN (1) CN1303067C (enExample)
AU (1) AU2001245694A1 (enExample)
BG (1) BG107585A (enExample)
BR (1) BR0113740A (enExample)
CA (1) CA2417177A1 (enExample)
CZ (1) CZ2003603A3 (enExample)
EA (1) EA005203B1 (enExample)
EE (1) EE200300093A (enExample)
HR (1) HRP20030163A2 (enExample)
HU (1) HUP0303934A2 (enExample)
IL (1) IL154080A0 (enExample)
MX (1) MXPA03001947A (enExample)
NO (1) NO20031065L (enExample)
NZ (1) NZ525169A (enExample)
PL (1) PL361038A1 (enExample)
SK (1) SK2862003A3 (enExample)
UA (1) UA73378C2 (enExample)
WO (1) WO2002020485A1 (enExample)
YU (1) YU17003A (enExample)
ZA (1) ZA200301032B (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
WO2000051624A2 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Methods and compositions useful in inhibiting apoptosis
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6773704B1 (en) * 1999-10-28 2004-08-10 The Brigham And Women's Hospital, Inc. Methods of treating vascular disease associated with cystatin C deficiency
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
MXPA03005601A (es) 2000-12-22 2004-12-02 Axys Pharm Inc Nuevos compuestos y composiciones como inhibidores de catepsina.
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
CA2439415C (en) * 2001-03-02 2011-09-20 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
US6982263B2 (en) * 2001-06-08 2006-01-03 Boehringer Ingelheim Pharmaceuticals, Inc. Nitriles useful as reversible inhibitors of cysteine proteases
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
IL160819A0 (en) 2001-09-14 2004-08-31 Aventis Pharma Inc Novel compounds and compositions as cathepsin inhibitors
AU2002340031A1 (en) * 2001-10-02 2003-04-14 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
CA2463770A1 (en) * 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
NZ532167A (en) 2001-11-14 2006-11-30 Aventis Pharma Inc Oligopeptides, their preparation and compositions containing them as cathepsin S inhibitors
AU2003256305A1 (en) * 2002-06-24 2004-01-06 Axys Pharmaceuticals, Inc. Peptidic compounds as cysteine protease inhibitors
US7326690B2 (en) * 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
US7465745B2 (en) * 2003-03-13 2008-12-16 Boehringer Ingelheim Pharmaceuticals, Inc. Cathepsin S inhibitors
US7326719B2 (en) * 2003-03-13 2008-02-05 Boehringer Ingelheim Pharmaceuticals, Inc. Cathepsin S inhibitors
US7384970B2 (en) * 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
US7109243B2 (en) * 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
WO2004089395A2 (en) * 2003-04-01 2004-10-21 Aventis Pharmaceuticals Inc. Use of an inhibitor of cathepsin-s or -b to treat or prevent chronic obstructive pulmonary disease
CA2526694A1 (en) * 2003-06-04 2004-12-16 John W. Patterson Amidino compounds as cysteine protease inhibitors
US7173051B2 (en) * 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7256207B2 (en) * 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
AU2004274471A1 (en) * 2003-09-18 2005-03-31 Virobay, Inc. Haloalkyl containing compounds as cysteine protease inhibitors
US7186827B2 (en) * 2003-10-30 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Dipeptide synthesis
UY28645A1 (es) * 2003-12-03 2005-06-30 Glaxo Group Ltd Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
JP2007513972A (ja) * 2003-12-11 2007-05-31 アクシス・ファーマシューティカルズ・インコーポレイテッド 低分子治療剤または生物製剤の投与によって引き起こされる免疫応答を治療するためのカテプシンｓインヒビターの使用
CN100548986C (zh) * 2003-12-12 2009-10-14 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
JP2007516295A (ja) * 2003-12-23 2007-06-21 アクシス・ファーマシューティカルズ・インコーポレイテッド システインプロテアーゼインヒビターとしてのアミジノ化合物
EP1819667B1 (en) * 2004-12-02 2012-10-17 ViroBay, Inc. Sulfonamide compounds as cysteine protease inhibitors
US20080125442A1 (en) * 2005-01-19 2008-05-29 Michael David Percival Cathepsin K Inhibitors and Atherosclerosis
KR101447897B1 (ko) 2005-03-21 2014-10-07 비로베이, 인코포레이티드 시스테인 단백질분해효소 억제제로서의 알파 케토아미드화합물
CA2602112A1 (en) * 2005-03-22 2006-09-28 Celera Genomics Sulfonyl containing compounds as cysteine protease inhibitors
US7282964B2 (en) * 2005-05-25 2007-10-16 Texas Instruments Incorporated Circuit for detecting transitions on either of two signal lines referenced at different power supply levels
EP1896032B1 (en) * 2005-06-14 2012-10-31 Merck Sharp & Dohme Corp. The preparation and use of compounds as protease inhibitors
US8067415B2 (en) * 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US7531671B2 (en) 2005-11-01 2009-05-12 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
US8067457B2 (en) * 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053495A2 (en) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
AU2007267470B2 (en) * 2006-06-01 2012-09-20 Sanofi-Aventis Spirocyclic nitriles as protease inhibitors
US8652844B2 (en) 2006-06-13 2014-02-18 The Curators Of The University Of Missouri Methods for the cryopreservation of animal cells that contain high levels of intracellular lipids
US8071625B2 (en) * 2006-08-02 2011-12-06 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8063082B2 (en) * 2006-08-02 2011-11-22 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP2079683B1 (en) * 2006-10-04 2015-01-21 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
US7893112B2 (en) 2006-10-04 2011-02-22 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
KR100877394B1 (ko) 2007-07-11 2009-01-07 한국화학연구원 카보니트릴 화합물을 포함하는 골다공증 및 치은 질환의치료 및 예방을 위한 약제학적 조성물
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
AU2008276512A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
JP5670731B2 (ja) * 2007-08-15 2015-02-18 サイトキネティクス・インコーポレーテッドＣｙｔｏｋｉｎｅｔｉｃｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ある種の化学物質、組成物、および方法
HRP20130552T1 (en) 2007-12-21 2013-08-31 Ligand Pharmaceuticals, Inc. Selective androgen receptor modulators (sarms) and uses thereof
WO2009087379A2 (en) 2008-01-09 2009-07-16 Amura Therapeutics Limited Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
SG193859A1 (en) * 2008-09-05 2013-10-30 Celgene Avilomics Res Inc Algorithm for designing irreversible inhibitors
EP2398320A4 (en) * 2009-02-19 2012-09-19 Univ Vanderbilt ALLOSTERIC ANTAGONISTS OF AMIDOBIPIPERIDINECARBOXYLATE M1, ANALOGUES AND DERIVATIVES THEREOF, AND METHODS FOR THEIR MANUFACTURE AND USE
US8324417B2 (en) 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
SG179172A1 (en) 2009-09-16 2012-04-27 Avila Therapeutics Inc Protein kinase conjugates and inhibitors
BR112012015721A2 (pt) 2009-12-30 2017-09-26 Avila Therapeutics Inc modificação covalente de proteínas dirigida por ligante
WO2012151319A1 (en) 2011-05-02 2012-11-08 Virobay, Inc. Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain
CN103764636A (zh) 2011-06-07 2014-04-30 株式会社吴羽 氧杂环丁烷化合物的制造方法、唑甲基环戊醇化合物的制造方法、以及中间体化合物
EP2537532A1 (en) 2011-06-22 2012-12-26 J. Stefan Institute Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
HUE033114T2 (en) 2011-11-18 2017-11-28 Heptares Therapeutics Ltd Muscarin M1 receptor agonists
EP2945929B1 (de) 2013-01-15 2020-01-22 Merck Patent GmbH Acylguanidine zur behandlung von arthrose
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
AU2020257397A1 (en) 2019-04-19 2021-12-16 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
CN111943848B (zh) * 2020-08-19 2023-05-05 苏州旺山旺水生物医药有限公司 一种elexacaftor中间体的制备方法及其应用

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3467691A (en) 1964-04-22 1969-09-16 Tsutomu Irikura N-(n-acylaminoacyl)-aminoacetonitriles
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
JPS4310619Y1 (enExample) 1967-02-16 1968-05-09
FI840260A7 (fi) 1983-01-27 1984-07-28 Ciba Geigy Ag Pyrrolidinonijohdannaiset ja menetelmä niiden valmistamiseksi.
US4767202A (en) * 1984-01-20 1988-08-30 Minolta Camera Kabushiki Kaisha Objective lens system for optical recording type disks
JPS61502124A (ja) * 1984-05-09 1986-09-25 ジ　オ−ストラリアン　ナシヨナル　ユニヴア−シテイ− 免疫応答の調節方法
US4797202A (en) 1984-09-13 1989-01-10 The Dow Chemical Company Froth flotation method
US4737425A (en) * 1986-06-10 1988-04-12 International Business Machines Corporation Patterned resist and process
JPS6358346A (ja) 1986-08-29 1988-03-14 Fuji Photo Film Co Ltd カラ−写真現像液組成物及びハロゲン化銀写真感光材料の処理方法
US4734425A (en) 1986-10-17 1988-03-29 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted hydroxamic acid prostaglandin analogs
US4749715A (en) 1987-03-02 1988-06-07 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted amino prostaglandin analogs
FR2615104B1 (fr) 1987-05-14 1989-08-18 Centre Nat Rech Scient Nouvelle protease de plasmodium falciparum, anticorps diriges contre cette protease, substrats peptidiques specifiques de ladite protease, et leur utilisation comme medicament contre le paludisme
JPS63301868A (ja) 1987-06-01 1988-12-08 Nippon Kayaku Co Ltd Ｎ−（２−クロロイソニコチノイル）アミノ酸誘導体およびそれを有効成分とする農園芸用殺菌剤
DE3719226A1 (de) 1987-06-09 1988-12-22 Bayer Ag (2-cyan-2-oximinoacetyl)-aminosaeure-derivate
US4971978A (en) 1987-09-21 1990-11-20 Nadzan Alex M Derivatives of D-glutamic acid and D-aspartic acid
AU2783189A (en) 1987-10-26 1989-05-23 Warner-Lambert Company Renin inhibitors, processes for preparing them, methods for using them, and compositions containing them
US5004743A (en) 1987-11-25 1991-04-02 Merck Frosst Canada, Inc. Pyridyl styrene dialkanoic acids as anti-leukotriene agents
US4962117A (en) 1987-11-25 1990-10-09 Merck Frosst Canada, Inc. Heterazole dialkanoic acids
CA1322005C (en) 1987-11-25 1993-09-07 Robert N. Young Benzoheterazoles
EP0442878A4 (en) 1988-04-05 1991-10-23 Abbott Laboratories Derivatives of tryptophan as cck antagonists
US5346907A (en) 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
AU3570089A (en) 1988-05-03 1989-11-29 Upjohn Company, The Renin inhibitory peptides containing a substituted phenoxyacetyle group
DE3827727A1 (de) 1988-08-16 1990-02-22 Boehringer Ingelheim Kg Anellierte tetrahydropyridinessigsaeurederivate, verfahren zu deren herstellung und verwendung solcher verbindungen zur kardioprotektion
EP0374098A3 (de) 1988-12-15 1991-05-02 Ciba-Geigy Ag Retrovirale Proteasehemmer
US5270302A (en) 1988-12-21 1993-12-14 Abbott Laboratories Derivatives of tetrapeptides as CCK agonists
GB8909836D0 (en) 1989-04-28 1989-06-14 Boots Co Plc Therapeutic agent
US5504109A (en) 1989-05-13 1996-04-02 Bayer Aktiengesellschaft Susbstituted amino acid amide derivatives their preparation and use
DE3915755A1 (de) 1989-05-13 1990-11-29 Bayer Ag Fungizide mittel sowie substituierte aminosaeureamid-derivate und deren herstellung
US5196291A (en) 1989-05-24 1993-03-23 Fuji Photo Film Co., Ltd. Silver halide photographic material
JP2658004B2 (ja) 1989-05-31 1997-09-30 キヤノン株式会社 電子写真感光体
JPH0462788A (ja) 1990-06-30 1992-02-27 Toshiba Corp 電子レンジ
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
JPH06145173A (ja) 1990-08-21 1994-05-24 Fujisawa Pharmaceut Co Ltd １−アザビシクロ［３．２．０］ヘプト−２−エン−２−カルボン酸化合物
JPH0511439A (ja) 1990-09-13 1993-01-22 Fuji Photo Film Co Ltd 光重合性組成物
DE4035961A1 (de) 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU9042191A (en) 1990-12-07 1992-07-08 Dyno Industrier A.S. System for utilization of wave energy
DE4104257A1 (de) 1991-02-13 1992-08-20 Boehringer Ingelheim Kg Verwendung von anellierten tetrahydropyridinessigsaeurederivaten fuer die behandlung neurologischer erkrankungen
US5461176A (en) 1991-03-27 1995-10-24 The Du Pont Merck Pharmaceutical Company Processes for preparing bis-naphthalimides containing amino-acid derived linkers
US5206249A (en) 1991-03-27 1993-04-27 Du Pont Merck Pharmaceutical Company Bis-naphthalimides containing amino-acid derived linkers as anticancer agents
US5190922A (en) 1991-06-04 1993-03-02 Abbott Laboratories Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands
JPH06510986A (ja) 1991-06-14 1994-12-08 カイロン　コーポレイション ピコルナウイルスプロテアーゼのインヒビター
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5298377A (en) 1991-08-28 1994-03-29 Eastman Kodak Company Photographic element with 2-equivalent magenta dye-forming coupler and filter dye
US5215876A (en) 1991-08-29 1993-06-01 Eastman Kodak Company Radiographic element with uv absorbation compound in polyester support
US5204349A (en) 1991-09-16 1993-04-20 Merck & Co., Inc. Amide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
JP2947539B2 (ja) 1991-11-12 1999-09-13 コニカ株式会社 ハロゲン化銀写真感光材料
DE69221290T2 (de) 1991-12-10 1998-01-15 Shionogi & Co Auf aromatischen sulfonamiden basierende hydroxamsäurederivate
EP0547699A1 (en) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
GB9200209D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
US5218123A (en) 1992-02-18 1993-06-08 Warner-Lambert Company Didehydrotryptophan derivatives and pharmaceutical use thereof
US5831002A (en) 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
JPH063787A (ja) 1992-06-18 1994-01-14 Konica Corp ハロゲン化銀写真感光材料用固形発色現像処理剤及び該固形発色現像処理剤を用いた処理方法
WO1994000435A1 (de) 1992-06-22 1994-01-06 Boehringer Ingelheim Kg Anellierte dihydropyridine und deren verwendung für die herstellung von pharmazeutischen zubereitungen
FR2694006A1 (fr) 1992-07-22 1994-01-28 Esteve Labor Dr Amides dérivés de benzohétérocyles.
DE4225487A1 (de) 1992-07-30 1994-02-03 Schering Ag Interphenylen-bicyclo(3.3.0)octan-Derivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
JPH0651451A (ja) 1992-07-31 1994-02-25 Konica Corp ハロゲン化銀写真感光材料用固形処理剤
JP3168547B2 (ja) 1992-08-18 2001-05-21 日本製粉株式会社 ポテト生地用ミックス、ポテト生地の製造法およびポテト生地を用いたフライ食品
JP3283114B2 (ja) 1992-09-07 2002-05-20 クミアイ化学工業株式会社 縮合ヘテロ環誘導体及び農園芸用殺菌剤
US5389682A (en) 1992-09-18 1995-02-14 Warner-Lambert Company Agents acting at cholecystokinin receptors
DE4232505A1 (de) 1992-09-29 1994-03-31 Degussa Verfahren zur Reduktion von Carbonsäuren oder Carbonsäurederivaten sowie neue Verbindungen
ES2150933T3 (es) 1992-12-22 2000-12-16 Lilly Co Eli Inhibidores de la proteasa vih utiles para el tratamiento del sida.
DE4303145A1 (de) 1993-01-30 1994-08-04 Schering Ag Interphenylen-2-Oxabicyclo(2.2.1)heptan-Derivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
WO1994021657A1 (en) 1993-03-18 1994-09-29 Pfizer Inc. Antibacterial 16-membered ring macrolides containing olefins at c-20
CA2159069A1 (en) 1993-03-29 1994-10-13 William Frank Degrado A process and intermediate compounds useful for the preparation of platelet glycoprotein iib/iiia inhibitors containing n -a- methylarginine
JPH06340643A (ja) 1993-04-04 1994-12-13 Nippon Nohyaku Co Ltd オキサゾ−ル又はチアゾ−ル誘導体及びその製造方法並びに除草剤
JP3165760B2 (ja) 1993-04-12 2001-05-14 株式会社トクヤマ 新規化合物
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
RO112859B1 (ro) 1993-04-28 1998-01-30 Kumiai Chemical Industry Co., Ltd. Derivaţi de amide de aminoacizi, procedee pentru prepararea acestora şi compoziţii fungicide care îi conţin
JPH0789951A (ja) 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
US5514778A (en) 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
DE4321897A1 (de) 1993-07-01 1995-01-12 Hoechst Schering Agrevo Gmbh Substituierte Aminosäureamid-Derivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und ihre Verwendung
DE4322067A1 (de) 1993-07-02 1995-01-12 Hoechst Schering Agrevo Gmbh Acylierte Aminophenylsulfonylharnstoffe; Darstellung und Verwendung als Herbizide und Wachstumsregulatoren
CH686479A5 (fr) 1993-08-11 1996-04-15 Nestle Sa Produit alimentaire a rehydratation rapide et son procede de preparation.
US5554753A (en) 1993-08-25 1996-09-10 Indiana University Foundation Catalytic enantioselective synthesis of α-amino acid derivatives by phase-transfer catalysis
JPH07101959A (ja) 1993-09-30 1995-04-18 Sankyo Co Ltd １−メチルカルバペネム誘導体
WO1995009838A1 (en) 1993-10-01 1995-04-13 Merrell Pharmaceuticals Inc. INHIBITORS OF β-AMYLOID PROTEIN PRODUCTION
IT1270882B (it) 1993-10-05 1997-05-13 Isagro Srl Oligopeptidi ad attivita' fungicida
JP3075657B2 (ja) 1993-10-15 2000-08-14 富士写真フイルム株式会社 写真用処理組成物及び処理方法
WO1995012611A1 (en) 1993-11-01 1995-05-11 Japat Ltd. Endothelin receptor antagonists
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
US5714484A (en) 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
DE4343528A1 (de) 1993-12-16 1995-06-22 Schering Ag Zweifach heterocyclisch substituierte Benzole und Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
EP0749418B1 (en) 1994-03-10 2000-08-30 G.D. Searle & Co. L-n6 -(1-iminoethyl)lysine derivatives useful as nitric oxide synthase inhibitors
EP0672654B1 (de) 1994-03-19 1997-09-10 Basf Aktiengesellschaft Fungizide Carbamoyloximcarbonsäureamide
JPH07285931A (ja) 1994-04-19 1995-10-31 Tokuyama Corp 新規化合物
DE4415049A1 (de) 1994-04-29 1995-11-02 Hoechst Schering Agrevo Gmbh Acylierte Aminophenylsulfonylharnstoffe, Verfahren zu deren Herstellung und Verwendung als Herbizide und Wachstumsregulatoren
DE4419517A1 (de) 1994-06-03 1995-12-07 Basf Ag Substituierte 3-Phenylpyrazole
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
DE4431467A1 (de) 1994-09-03 1996-03-07 Basf Ag Caramoylcarbonsäureamide
CA2200981A1 (en) 1994-10-04 1996-04-11 Hisashi Takasugi Urea derivatives and their use as acat-inhibitors
NZ293741A (en) 1994-10-26 1998-06-26 Upjohn Co 3-[4-(azetidin-1-yl or pyrrolidin-1-yl)phenyl]-5-aminomethyloxazolidin-2-one amide derivatives
CA2163325A1 (en) 1994-11-21 1996-05-22 Kaneyoshi Kato Amine compounds, their production and use
WO1996016940A1 (en) 1994-12-02 1996-06-06 Yamanouchi Pharmaceutical Co., Ltd. Novel amidinonaphthyl derivative or salt thereof
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5863902A (en) 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5691368A (en) 1995-01-11 1997-11-25 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin B inhibitors
DE19501841A1 (de) 1995-01-23 1996-07-25 Bayer Ag Aminosäureamide
DE19505932B4 (de) 1995-02-21 2005-06-23 Degussa Ag Verfahren zur Herstellung von Oxazolidinonen, neue Oxazolidinone sowie Verwendung von Oxazolidinonen
US5710129A (en) 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes
JPH08248579A (ja) 1995-03-14 1996-09-27 Mitsubishi Paper Mills Ltd ハロゲン化銀写真感光材料及びその処理方法
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
KR19980703261A (ko) 1995-03-24 1998-10-15 다니엘 이이치. 페트리 가역성 프로테아제 억제제
IN186549B (enExample) 1995-04-19 2001-09-29 Kumiai Chemical Co Ltd
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
WO1996033170A1 (en) 1995-04-21 1996-10-24 Novarits Ag N-aroylamino acid amides as endothelin inhibitors
JPH08319291A (ja) 1995-05-25 1996-12-03 Meiji Seika Kaisha Ltd 新規セフェム誘導体
JP3314938B2 (ja) 1995-06-06 2002-08-19 ファイザー・インコーポレーテッド グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体
US5756528A (en) 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6069130A (en) 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5827860A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors
US5827866A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
WO1996040753A1 (en) 1995-06-07 1996-12-19 G.D. Searle & Co. Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis
WO1997001275A1 (en) 1995-06-29 1997-01-16 Merck & Co., Inc. Combinations of inhibitors of farnesyl-protein transferase
KR19990028753A (ko) 1995-07-07 1999-04-15 곤도 기요시 펩티드 유도체 및 안지오텐신 iv 수용체 작동약
GB9518552D0 (en) 1995-09-11 1995-11-08 Fujisawa Pharmaceutical Co New heterocyclic compounds
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
AU7710596A (en) 1995-11-29 1997-06-19 Nihon Nohyaku Co., Ltd. Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides
TW474946B (en) 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US5843904A (en) 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US6057451A (en) 1995-12-29 2000-05-02 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-herpesvirus compounds and methods for identifying, making and using same
WO1997026246A1 (en) 1996-01-16 1997-07-24 Warner-Lambert Company Substituted histidine inhibitors of protein farnesyltransferase
WO1997027200A1 (en) 1996-01-26 1997-07-31 Smithkline Beecham Plc Thienoxazinone derivatives useful as antiviral agents
US6288037B1 (en) 1996-01-29 2001-09-11 Basf Aktiengesellschaft Substrates and inhibitors for cysteine protease ICH-1
AU2277597A (en) 1996-02-23 1997-09-10 Ariad Pharmaceuticals, Inc. New inhibitors of sh2-mediated processes
DE19609955A1 (de) 1996-03-14 1997-09-18 Basf Ag Amidonitrile, Verfahren zu ihrer Herstellung, ihre Verwendung als Kaltbleichaktivatoren oder optische Aufheller in Wasch-, Reinigungs- und Bleichmitteln sowie ihre Verwendung als Ausgangsmaterial bei der Herstellung von Amidocarbonsäuren und Amidocarbonsäure-Derivaten
CA2204082A1 (en) 1996-05-03 1997-11-03 Michael William John Urquhart Pharmaceutical compounds
DE19621522A1 (de) 1996-05-29 1997-12-04 Hoechst Schering Agrevo Gmbh Neue N-Acylsulfonamide, neue Mischungen aus Herbiziden und Antidots und deren Verwendung
DE19621483A1 (de) 1996-05-29 1997-12-04 Hoechst Ag Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6124345A (en) 1996-05-31 2000-09-26 Basf Aktiengesellschaft Carbamoyl carboxylic acid amide oximes
DE19629717C1 (de) 1996-07-25 1998-02-12 Hoechst Ag Verfahren zur katalytischen Herstellung von N-Acylglycinderivaten
US5939527A (en) 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
ES2239779T3 (es) 1996-10-02 2005-10-01 Novartis Ag Derivados de pirimidina y procedimientos para la preparacion de los mismos.
ID21649A (id) 1996-10-18 1999-07-08 Vertex Pharma Inhibitor serum protease, terutama virus hepatitis c ns3 protease
EP0844248B1 (de) 1996-10-28 2002-07-10 Rolic AG Vernetzbare, photoaktive Silanderivate
EP0941222A2 (en) 1996-11-12 1999-09-15 Novartis AG Pyrazole derivatives useful as herbicides
IL129504A0 (en) 1996-11-22 2000-02-29 Elan Pharm Inc N-(aryl/heteroaryl/alkylacetyl) amino acid amides pharmaceutical compositions comprising same and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
US5952322A (en) 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
DE69718835T2 (de) 1996-12-19 2003-12-24 Isagro S.P.A., Mailand/Milano Verfahren zur Herstellung von (N-Phenylacetyl-N-2,6-xylyl)methyl Alaninat
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
HUP0000735A3 (en) 1996-12-23 2002-03-28 Bristol Myers Squibb Pharma Co Nitrogen containing heteroaromatics as factor xa inhibitors
HRP980093A2 (en) 1997-02-28 1998-12-31 Lilly Co Eli Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting "beta"-amyloid peptide release and/or its synthesis by use of such compounds
FR2762315B1 (fr) 1997-04-22 1999-05-28 Logeais Labor Jacques Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha
WO1998052941A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
DE1019040T1 (de) 1997-05-23 2001-02-08 Bayer Corp., West Haven Hemmung von p38 kinase aktivität durch arylharnstoff
ES2153337T3 (es) 1997-05-23 2008-11-01 Bayer Pharmaceuticals Corporation Inhibidores de la quinasa raf.
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
JP2002507968A (ja) 1997-06-19 2002-03-12 デュポン ファーマシューティカルズ カンパニー 中性のＰ１特異性基を有するＸａ因子阻害剤
EP0897908A1 (de) 1997-08-19 1999-02-24 Roche Diagnostics GmbH 3-Aryl-Succinamido-Hydroxamsäuren, Prozesse zu ihrer Herstellung und diese Substanzen enthaltende Medikamente
JPH11100373A (ja) 1997-09-26 1999-04-13 Eisai Co Ltd 新規フェノチアジン誘導体及びその医薬
US5872122A (en) 1997-10-16 1999-02-16 Monsanto Company Pyrimidinylamidino β-amino acid derivatives useful as inhibitors of platelet aggregation
WO1999023063A1 (en) 1997-10-31 1999-05-14 Aventis Pharma Limited Substituted anilides
PL202226B1 (pl) 1997-11-05 2009-06-30 Novartis Ag Nitryl dipeptydowy, jego zastosowanie lecznicze i zawierająca go kompozycja farmaceutyczna
ATE300299T1 (de) 1997-12-22 2005-08-15 Bayer Pharmaceuticals Corp Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
EP1056725B1 (en) 1997-12-22 2006-06-07 Bayer Pharmaceuticals Corp. Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
CN1308542A (zh) 1998-05-05 2001-08-15 沃纳-兰伯特公司 白介素－1β转化酶的琥珀酰胺抑制剂
US6387629B1 (en) 1998-06-04 2002-05-14 Reprogen, Inc. Use of cathepsin S in the diagnosis and treatment of endometriosis
EP1159273A1 (en) 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cathepsin s
EE04911B1 (et) 1999-03-15 2007-10-15 Axys Pharmaceuticals, Inc. Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
WO2001012864A1 (fr) * 1999-08-10 2001-02-22 Nkk Corporation Procede de production de feuillards d'acier lamines a froid
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
WO2001019816A1 (en) * 1999-09-13 2001-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
WO2001020051A1 (en) * 1999-09-16 2001-03-22 Nkk Corporation Steel thin plate having high strength and method for production thereof
EP1170390A4 (en) * 1999-09-28 2005-02-23 Jfe Steel Corp HOT ROLLED STEEL SHEET HAVING HIGH TENSILE STRENGTH RESISTANCE AND PROCESS FOR PRODUCING THE SAME
DE60045303D1 (de) * 1999-09-29 2011-01-13 Jfe Steel Corp Stahlblech und verfahren zu dessen herstellung
EP1143019B1 (en) * 1999-09-29 2014-11-26 JFE Steel Corporation Method for manufacturing a coiled steel sheet
CN1331183A (zh) 2000-06-28 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人dna修复蛋白10.23和编码这种多肽的多核苷酸

Also Published As

Publication number Publication date
NO20031065D0 (no) 2003-03-07
US20030216383A1 (en) 2003-11-20
US7279472B2 (en) 2007-10-09
US20030232826A1 (en) 2003-12-18
EA200300348A1 (ru) 2003-08-28
NZ525169A (en) 2004-11-26
ZA200301032B (en) 2004-04-21
US6787540B2 (en) 2004-09-07
KR20030051644A (ko) 2003-06-25
BR0113740A (pt) 2003-06-24
CN1471511A (zh) 2004-01-28
MXPA03001947A (es) 2003-06-24
US20050032772A1 (en) 2005-02-10
HUP0303934A2 (hu) 2004-04-28
YU17003A (sh) 2006-03-03
US20020137932A1 (en) 2002-09-26
EE200300093A (et) 2005-02-15
US6982272B2 (en) 2006-01-03
US6420364B1 (en) 2002-07-16
SK2862003A3 (en) 2003-08-05
US6720319B2 (en) 2004-04-13
US20050032792A1 (en) 2005-02-10
US20040006078A1 (en) 2004-01-08
US6525052B2 (en) 2003-02-25
BG107585A (bg) 2003-11-28
US7265132B2 (en) 2007-09-04
UA73378C2 (en) 2005-07-15
US20030225270A1 (en) 2003-12-04
JP2004508356A (ja) 2004-03-18
HRP20030163A2 (en) 2005-04-30
EP1322613A1 (en) 2003-07-02
EA005203B1 (ru) 2004-12-30
NO20031065L (no) 2003-03-07
US20020058809A1 (en) 2002-05-16
CN1303067C (zh) 2007-03-07
PL361038A1 (en) 2004-09-20
US6756372B2 (en) 2004-06-29
CZ2003603A3 (cs) 2003-06-18
US6858623B2 (en) 2005-02-22
US20030225271A1 (en) 2003-12-04
WO2002020485A1 (en) 2002-03-14
AU2001245694A1 (en) 2002-03-22
CA2417177A1 (en) 2002-03-14
US7056915B2 (en) 2006-06-06
HK1060565A1 (en) 2004-08-13

Similar Documents

Publication Publication Date Title
IL154080A0 (en) Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases
IL148184A0 (en) Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
PL370766A1 (en) Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
AU2002340031A1 (en) Compounds useful as reversible inhibitors of cysteine proteases
GB0125445D0 (en) Protease Inhibitors
IL150406A0 (en) Dipeptide nitrile cathepsin k inhibitors
AU2002305926A1 (en) Cysteine protease inhibitors
AP2002002593A0 (en) Protease inhibitors
NZ513885A (en) C-terminal modified (N-substituted)-2-indolylcarbonyldipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
GB9917909D0 (en) Cysteine protease inhibitors
AU2002211464A1 (en) Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl- substituted phenyl acetamides as protease inhibitors
GB9907683D0 (en) Substituted azetidin-2-ones as cysteine protease inhibitors
AU2001245764A1 (en) Novel compounds and compositions as protease inhibitors
IL160819A0 (en) Novel compounds and compositions as cathepsin inhibitors
IL159125A0 (en) Novel compounds and compositions as cathepsin inhibitors
AU2003298740A1 (en) Cyanomethyl derivatives as cysteine protease inhibitors
EP1401453A4 (en) PROTEASE INHIBITORS
IL155961A0 (en) Cysteine protease inhibitors
AU2001229398A1 (en) Inhibitors of the ice/ced-3 family of cysteine proteases
AU2001253633A1 (en) Inhibitors of the ice/ced-3 family of cysteine proteases
AU2002314898A1 (en) Novel nitriles useful as reversible inhibitors of cysteine proteases
ZA200201987B (en) Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases.
AU2002335889A1 (en) Compounds useful as reversible inhibitors of cysteine proteases
AU2002346812A1 (en) Use of 1-phenyl-oxazolidine-2-one compounds as protease m inhibitors
AU2001296247A1 (en) Cysteine protease inhibitors